Core Insights - Pan American Silver (PAAS) is expected to report quarterly earnings of $0.49 per share, a 53.1% increase year-over-year, with revenues projected at $867.76 million, reflecting a 21.2% year-over-year growth [1] Earnings Estimates - The consensus EPS estimate has been revised 17.6% higher in the last 30 days, indicating a collective reevaluation by analysts [2] - Revisions to earnings projections are crucial for predicting investor behavior and are linked to short-term stock price performance [3] Production Estimates - Analysts estimate gold production at 184 thousand ounces, down from 225 thousand ounces year-over-year [5] - Silver production is expected to be 5843 thousand ounces, up from 5467 thousand ounces year-over-year [5] - La Colorada Operation's silver production is projected at 1462 thousand ounces, an increase from 1329 thousand ounces year-over-year [6] - Huaron Operation's silver production is estimated at 818 thousand ounces, down from 888 thousand ounces year-over-year [6] - San Vicente Operation's silver production is expected to be 721 thousand ounces, down from 811 thousand ounces year-over-year [7] - Dolores Operation's silver production is projected at 208 thousand ounces, significantly down from 442 thousand ounces year-over-year [7] - Gold production at Dolores Operation is expected to be 6 thousand ounces, down from 18 thousand ounces year-over-year [8] - Timmins Operation's gold production is estimated at 27 thousand ounces, down from 34 thousand ounces year-over-year [8] Price and Cost Estimates - Average realized price per ounce of silver is expected to reach $39.11, up from $29.52 year-over-year [9] - Average realized price per ounce of gold is projected at $3448.99, compared to $2475.00 year-over-year [9] - Cash costs per ounce for the silver segment are estimated at $12.85, down from $15.88 year-over-year [10] - Cash costs per ounce for the gold segment are projected at $1350.82, up from $1195.00 year-over-year [10] Market Performance - Shares of Pan American Silver have decreased by 12.2% in the past month, contrasting with a -0.2% change in the Zacks S&P 500 composite [11] - The company holds a Zacks Rank 2 (Buy), indicating expectations of outperforming the overall market in the near future [11]

Core Viewpoint - Analysts forecast that GlobalFoundries Inc. (GFS) will report quarterly earnings of $0.38 per share, reflecting a year-over-year decline of 7.3%, with anticipated revenues of $1.68 billion, a decrease of 3.7% compared to the previous year [1] Earnings Estimates - Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter, indicating that analysts have not changed their initial forecasts during this period [2] - Changes in earnings estimates are crucial for predicting potential investor reactions, as empirical studies show a strong relationship between earnings estimate revisions and short-term stock price performance [3] Revenue Projections - Analysts project that 'Net revenue- Type of goods and services- Wafer fabrication' will reach $1.49 billion, indicating a year-over-year change of -4.6% [5] - The consensus for 'Net revenue- End Market- Smart Mobile Devices' is expected to be $669.73 million, reflecting a decline of 22.8% year-over-year [5] - The estimate for 'Net revenue- End Market- Non wafer revenue' stands at $199.97 million, showing a year-over-year increase of 14.9% [6] - Analysts expect 'Net revenue- End Market- Home and Industrial IoT' to be $274.00 million, indicating a year-over-year change of -11% [6] - 'Net revenue- End Market- Automotive' is projected at $367.06 million, suggesting a significant increase of 43.4% year-over-year [6] - The average prediction for 'Net revenue- End Market- Communications Infrastructure & Datacenter' is $181.79 million, reflecting a year-over-year increase of 36.7% [7] Shipment Volume - Analysts suggest that 'Wafer shipment volume' will likely reach 577, compared to 549 in the previous year [7] Stock Performance - Shares of GlobalFoundries have experienced a change of -2.6% in the past month, contrasting with the -0.2% move of the Zacks S&P 500 composite [7] - With a Zacks Rank 3 (Hold), GFS is expected to mirror the overall market performance in the near future [7]

Core Insights - Cisco Systems (CSCO) is expected to report quarterly earnings of $0.98 per share, a 7.7% increase year-over-year, with revenues projected at $14.78 billion, reflecting a 6.8% year-over-year growth [1] Earnings Estimates - The consensus EPS estimate has been revised downward by 0.2% over the past 30 days, indicating a collective reassessment by analysts [2] - Changes in earnings estimates are crucial for predicting investor reactions, with empirical studies showing a strong correlation between earnings estimate revisions and short-term stock performance [3] Revenue Projections - Analysts estimate 'Revenue- Product- Networking' to reach $7.34 billion, an increase of 8.7% year-over-year [5] - 'Revenue- Product- Observability' is projected at $288.48 million, indicating an 11.8% increase from the previous year [5] - 'Revenue- Services' is expected to be $3.80 billion, reflecting a 2% year-over-year change [5] - 'Revenue- Product- Security' is forecasted at $2.24 billion, an 11% increase from the year-ago quarter [6] - The overall 'Revenue- Product' is anticipated to reach $10.95 billion, showing an 8.3% year-over-year growth [6] - 'Revenue- Product- Collaboration' is estimated at $1.09 billion, with a minimal increase of 0.2% year-over-year [6] Gross Margin Estimates - Analysts predict 'Non-GAAP Gross Margin- Service' to be $2.69 billion, compared to $2.62 billion in the same quarter last year [7] - The average estimate for 'Non-GAAP Gross Margin- Product' is $7.38 billion, up from $6.97 billion year-over-year [7] Stock Performance - Over the past month, Cisco shares have gained 1.5%, while the Zacks S&P 500 composite has decreased by 0.2% [7] - Cisco holds a Zacks Rank of 3 (Hold), suggesting its performance will likely align with the overall market in the near term [7]

Core Insights - Health Catalyst (HCAT) is expected to report quarterly earnings of $0.05 per share, reflecting a year-over-year decline of 28.6% [1] - Revenue projections stand at $75.08 million, indicating a decrease of 1.7% compared to the same quarter last year [1] - The consensus EPS estimate has remained unchanged over the last 30 days, suggesting analysts have reevaluated their initial estimates [1][2] Revenue Estimates - Analysts predict 'Revenue- Professional services' will reach $23.08 million, a decline of 16.7% from the prior-year quarter [4] - 'Revenue- Technology' is estimated at $52.00 million, showing a year-over-year increase of 6.9% [4] Profit Estimates - The average prediction for 'Adjusted Gross Profit- Professional Services' is $4.45 million, down from $4.72 million reported in the same quarter last year [5] - The consensus estimate for 'Adjusted Gross Profit- Technology' is $34.90 million, compared to $31.57 million reported in the same quarter last year [5] Stock Performance - Health Catalyst shares have increased by 7% over the past month, outperforming the Zacks S&P 500 composite, which rose by 1.3% [5] - The company holds a Zacks Rank 3 (Hold), indicating it is expected to closely follow overall market performance in the near term [5]

Core Insights - Amdocs (DOX) is expected to report quarterly earnings of $1.82 per share, a 7.1% increase year-over-year, while revenues are forecasted to decline by 9.6% to $1.14 billion [1] - The consensus EPS estimate has remained stable over the past 30 days, indicating analysts have reassessed their initial projections [1][2] Revenue Estimates - Managed Services Revenue is estimated at $744.28 million, reflecting a year-over-year increase of 3.2% [4] - North America revenue is projected to be $747.81 million, indicating a decline of 10.5% year-over-year [4] - Revenue from the Rest of the World is expected to reach $220.41 million, down 9.7% from the previous year [4] - European revenue is forecasted at $172.12 million, showing a decrease of 6.5% compared to the same quarter last year [5] Stock Performance - Over the past month, Amdocs shares have gained 2%, outperforming the Zacks S&P 500 composite, which increased by 1.3% [5] - Amdocs holds a Zacks Rank 3 (Hold), suggesting its performance will likely align with the overall market in the near term [5]

Core Insights - Wall Street analysts expect Kamada (KMDA) to report quarterly earnings of $0.10 per share, reflecting a year-over-year increase of 42.9% [1] - Revenue projections for Kamada are set at $46.25 million, which indicates a 10.8% increase compared to the same quarter last year [1] Earnings Estimates - There have been no revisions in the consensus EPS estimate for the quarter over the last 30 days, indicating stability in analysts' forecasts [1][2] - Changes in earnings estimates are crucial for predicting investor reactions and are strongly correlated with short-term stock performance [2] Revenue Breakdown - Analysts predict 'Revenues- Distribution' will reach $5.45 million, representing an 18.1% year-over-year increase [4] - 'Revenues- Proprietary products' are expected to be $40.80 million, showing a 9.9% year-over-year growth [4] - The estimated 'Gross Profit- Proprietary products' is projected to be $18.81 million, compared to $16.26 million from the previous year [4] Stock Performance - Over the past month, Kamada's shares have returned +1%, slightly underperforming the Zacks S&P 500 composite's +1.3% [5] - Kamada currently holds a Zacks Rank 2 (Buy), suggesting potential outperformance in the near future [5]

Core Insights - Somnigroup International (SGI) is expected to report quarterly earnings of $0.85 per share, reflecting a 3.7% increase year over year, with revenues projected at $2.07 billion, a significant 59% year-over-year growth [1]. Earnings Estimates - The consensus EPS estimate has been revised upward by 4.2% in the last 30 days, indicating analysts' reassessment of their initial projections [2]. - Changes in earnings estimates are crucial for predicting investor reactions, as empirical research shows a strong correlation between earnings estimate revisions and short-term stock performance [3]. Revenue Projections - Analysts estimate 'Net Sales- Direct' at $1.32 billion, representing a remarkable increase of 316.1% from the previous year [5]. - 'Net Sales- Wholesale' is projected to be $716.71 million, indicating a decrease of 27% year over year [5]. - 'Net Sales- International' is expected to reach $308.79 million, reflecting an 8.5% increase from the prior year [5]. Regional Sales Estimates - 'Net Sales- North America' is anticipated to be $732.72 million, showing a decline of 27.8% from the previous year [6]. - 'Net Sales- North America- Wholesale' is forecasted at $605.19 million, indicating a year-over-year decrease of 31.1% [6]. - 'Net Sales- International- Direct' is estimated at $196.52 million, reflecting an 8.4% increase from the prior year [6]. Additional Sales Insights - 'Net Sales- International- Wholesale' is projected to be $111.52 million, suggesting a year-over-year increase of 7.9% [7]. - 'Net Sales- North America- Direct' is expected to reach $107.39 million, indicating a decline of 21.6% year over year [7]. Market Performance - SGI shares have shown a return of -4.4% over the past month, contrasting with the Zacks S&P 500 composite's +1% change [7]. - With a Zacks Rank 2 (Buy), SGI is anticipated to outperform the overall market in the near future [7].

Core Viewpoint - Wall Street analysts predict that Globus Medical (GMED) will report quarterly earnings of $0.79 per share, reflecting a year-over-year decline of 4.8%, while revenues are expected to reach $733.45 million, marking a 17.2% increase compared to the same quarter last year [1]. Earnings Estimates - Over the past 30 days, the consensus EPS estimate has been revised downward by 1.3%, indicating a collective reassessment by covering analysts [2]. - Revisions to earnings estimates are crucial as they serve as significant indicators for predicting potential investor actions regarding the stock [3]. Revenue Projections - Analysts expect 'Net Sales by Product Category - Enabling Technologies' to be $40.23 million, showing a year-over-year increase of 5% [5]. - The consensus for 'Net Sales by Product Category - Musculoskeletal Solutions' is projected at $693.98 million, reflecting an 18.1% increase from the prior-year quarter [5]. - The average prediction for 'Geographic Revenues - International' is $144.37 million, indicating an 11.1% increase from the year-ago quarter [6]. - 'Geographic Revenues - United States' are forecasted to reach $589.84 million, representing a 19% increase from the prior-year quarter [6]. Stock Performance - Globus Medical shares have increased by 4% over the past month, outperforming the Zacks S&P 500 composite, which has seen a 1% increase [6]. - The company holds a Zacks Rank 3 (Hold), suggesting it is expected to closely follow overall market performance in the near term [6].

Core Insights - Tyson Foods (TSN) is expected to report quarterly earnings of $0.85 per share, reflecting a decline of 7.6% year-over-year, while revenues are forecasted to reach $13.91 billion, indicating a 2.5% increase compared to the previous year [1] Earnings Estimates - Over the past 30 days, the consensus EPS estimate has been revised upward by 5.1%, indicating analysts' reassessment of their initial forecasts [2] - Changes in earnings estimates are crucial for predicting investor reactions, with empirical studies showing a strong correlation between earnings estimate revisions and short-term stock price performance [3] Sales Projections - Analysts project 'Sales- Chicken' to reach $4.30 billion, reflecting a year-over-year increase of 1.1% [4] - 'Sales- Beef' is expected to be $5.45 billion, indicating a 3.7% increase from the previous year [5] - 'Sales- International/Other' is forecasted at $612.05 million, showing a 0.5% increase year-over-year [5] - 'Sales- Prepared Foods' is estimated to reach $2.51 billion, suggesting a 1.5% increase compared to the prior year [5] - 'Sales- Pork' is projected to be $1.52 billion, indicating a 6% increase year-over-year [6] Adjusted Operating Income Estimates - The consensus for 'Adjusted Operating Income (Loss)- Pork' is estimated at $23.28 million, up from $19.00 million in the previous year [6] - 'Adjusted Operating Income (Loss)- International/Other' is projected at $13.80 million, compared to $3.00 million reported in the same quarter last year [7] - 'Adjusted Operating Income (Loss)- Prepared Foods' is expected to be $212.35 million, up from $205.00 million year-over-year [7]

Core Viewpoint - EverQuote (EVER) shares have shown a modest gain of 0.4% over the past four weeks, closing at $22.41, with analysts suggesting a potential upside of 48% based on a mean price target of $33.17 [1] Price Targets and Analyst Consensus - The average price target for EVER is based on six short-term estimates, ranging from a low of $29.00 to a high of $38.00, with a standard deviation of $3.43, indicating a potential increase of 29.4% to 69.6% from the current price [2] - A low standard deviation suggests strong agreement among analysts regarding the price movement of EVER, which can serve as a starting point for further research [9] Earnings Estimates and Market Sentiment - Analysts have shown increasing optimism about EVER's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which correlates strongly with near-term stock price movements [11] - Over the last 30 days, one earnings estimate has increased, leading to a 0.1% rise in the Zacks Consensus Estimate for the current year [12] Zacks Rank and Investment Potential - EVER holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating a strong potential upside [13] - While the consensus price target may not be entirely reliable, the implied direction of price movement appears to be a useful guide for investors [14]